The impact of treatment with secukinumab and other biologics on other cardiometabolic risk factors, such as hypertension, adiponectin levels, dyslipidaemia and hyperuricemia, is also limited in patients with metabolic comorbidities [33,35]. The gene discussed is ADIPOQ; the disease is inherited lipid metabolism disorder.